baber/WOPTO huggingface dataset:
Patent NZ-537718-A (NZ)
Title: Rotor for permanent magnet motor of outer rotor type
Inventor: SHIGA TSUYOSHI
IPC: H02K15/03
Filed: 2003-06-16
Abstract: A rotor (16) for a permanent magnet motor of an outer rotor type is disclosed, where the rotor (16) has a plurality of permanent magnets (19) and is disposed around a stator. The rotor (16) comprises a frame (17), an annular iron core (18) combined integrally with the frame (17), and a plurality of insertion holes (25) formed in the core (18). The permanent magnets (19) are inserted in the insertion holes (25), and the frame (17), the core (18) and the permanent magnets (19) are combined integrally with one another by a synthetic resin (35). Each insertion hole (25) includes a magnet disposing portion (25a) in which the permanent magnet (19) is disposed, a space portion located in at least one of both ends of each permanent magnet disposed in the magnet disposing portion (25a), and a positioning portion (26) that positions each permanent magnet in the magnet disposing portion (25a). The rotor is combined integrally when the molten synthetic resin (35) is poured into the space portion.
Patent NZ-540563-A (NZ)
Title: Proteorhodopsin mutant comprising a mutation in a conserved histidine that gives the mutant improved optical characteristics
Inventor: JENSEN RASMUS B
IPC: C12Q1/68
Filed: 2003-11-26
Abstract: Disclosed is a proteorhodopsin mutant comprising a mutation in a conserved histidine residue of a wild-type proteorhodopsin variant, wherein the proteorhodopsin mutant has lower pKrh or less difference in maximum absorption wavelength between a basic and an acidic form in comparison with that of wild-type proteorhodopsin variant, wherein said conserved histidine is mutated to an amino acid capable of forming a hydrogen bond.
Patent NZ-542712-A (NZ)
Title: Medicament dispensing device with a display indicative of the state of an internal medicament reservoir
Inventor: BARNEY BRIAN
IPC: A61L9/04
Filed: 2004-03-04
Abstract: A medicament inhaler that is able to display information about the medicament container placed within it. The container has some means of storing information about itself which is coupled with a particular inhaler housing. The housing stores this information to validate the identity of the container on insertion. The housing also has means to detect the movement of the container, indicative of a dose of medicament being delivered, so that an indication of remaining medication can be presented. A warning that the medication remaining is below a set point or points can be given to the user.
Patent NZ-545001-A (NZ)
Title: Zeolites for delivery of nitric oxide
Inventor: MORRIS RUSSELL EDWARD
IPC: A61Q5/00
Filed: 2004-07-05
Abstract: Disclosed are zeolites comprising releasably adsorbed nitric oxide (NO) which are useful in the treatment or prophylaxis of diseases or medical conditions. Also disclosed are medical articles, cosmetic and personal hygiene products comprising the zeolites.
Patent NZ-548040-A (NZ)
Title: Use of alkylphosphocholines for the preventative treatment of protozoan diseases such as especially leishmaniasis
Inventor: ENGEL JURGEN
IPC: A61P1/08
Filed: 2003-01-07
Abstract: Disclosd herein is a use of the alkyiphosphocholine hexadecylphosphocholine (miltefosine) or octadecyl 1,1,-dimethylpiperidinio-4-yl phosphate (perifosine) for producing a medicament for the preventive treatment of leishmaniasis in humans by oral administration, the medicament being adapted to provide a total daily dose in the range from 10 to 250 mg of miltefosine or perifosine active ingredient orally over a period of from 2 weeks to 6 months.
Patent NZ-549520-A (NZ)
Title: Tamper-indicating closure that uses deformable wings inside a frangable ring that engage teeth on neck of bottle
Inventor: BLOOM KENNETH S
IPC: B65D41/34
Filed: 2005-03-04
Abstract: A tamper-indicating closure (28) on a container is disclosed. The closure includes a base wall (36) having a cylindrical skirt for engaging the container, a tamper band (50) frangibly connected to the skirt, and a plurality of wings (58) extending inwardly from an inner surface of the tamper band (50) for engaging projections from the container. The wings (58) are flexibly resiliently connected to the inner surface of the band (50) along lines that are disposed at a counter-clockwise angle with respect to an axis of the skirt as viewed from inside the skirt. This arrangement allows the closure (28) to be screwed onto the container as the wings (58) deform to pass the projections but when the closure (28) is removed, the wings (58) engage the projections in such a way that they prevent the movement of the tamper band (50) relative to the rest of the closure (28) causing the frangible connections (52) between the base wall (36) and the tamper band (50) to break. This indicates the closure (28) has been opened.
Patent NZ-550224-A (NZ)
Title: A film that uses an oxide of nitrogen to create nitroxymyoglobin and maintain the red colour of fresh meat
Inventor: SIEGEL DAN G
IPC: A23L13/00
Filed: 2005-04-04
Abstract: A food packaging film (22) is disclosed. The film is used in creating and stabilizing a desirable colour on the surface of a food (100), such as raw meat without deleteriously affecting the subsurface colour. The film (22) comprises a food contact layer and a nitrogen oxide-containing compound. The film forms a package (10') to hold the food (100) and also acts as an oxygen barrier. The nitrogen oxide-containing compound interacts with myoglobin in the food (100) to produce the desirable colour. The amount of nitrogen oxide-containing compound is insufficient to cure the entire food (100) and is present at a transferable amount of at least 1.24 milligrams per square meter (0.0008 milligrams per square inch) at the surface of the film.
Patent NZ-552453-A (NZ)
Title: Genetic manipulation of condensed tannins
Inventor: DIXON RICHARD A
IPC: C12N15/82
Filed: 2005-07-11
Abstract: Provided is a transgenic plant transformed with a first selected DNA encoding TT2 and a second selected DNA encoding a BAN polypeptide, wherein the plant expresses the first selected DNA encoding TT2 and exhibits increased condensed tannin biosynthesis relative to a second plant that differs from the transgenic plant only in that the first selected DNA is absent. Further provided are methods of producing said plants and methods of producing human food using said plants.
Patent NZ-555469-A (NZ)
Title: Method and apparatus for waking a person
Inventor: ASHLEY ERIN
IPC: G08B3/00
Filed: 2005-12-05
Abstract: A device suitable for waking a hearing impaired person is disclosed. The device includes a circuit for generating a driver signal in response to an alarm signal. The driver signal has a repeating irregular interrupted pattern including a plurality of "on" periods and a plurality of "off' periods. At least one "on" period has a duration different from at least one "off" period and at least one "off' period has a duration different from at least one other "off' period. The device also includes an electrically controlled switching device which has a control input connected to receive the driver signal from the circuit, a power input connectable to a power source and a power output. The device also includes a tactile stimulation device connected to the power output of the electrically controlled switching device. The tactile stimulation device produces a tactile stimulation corresponding to the driver signal, where a person sensing the tactile stimulation is awakened.
Patent NZ-568655-A (NZ)
Title: Stator end disk for a commutator motor and corresponding commutator motor
Inventor: BINDER ALFRED
IPC: H02K3/52
Filed: 2006-12-06
Abstract: A stator end disk for a laminated stator core of a commutator motor comprising a connecting terminal 11 which has connecting elements 24 for connecting stator winding wires and a female connector 28 with contact elements 25 for receiving and electrically connecting an external motor connector, whereby each of the connecting elements 24 is connected in each case to an associated contact element 25 so as to be electrically conducting, wherein only one connecting terminal 11 is arranged on the stator end disk, and that in order to electrically connect at least one further internal, electrical component 31 of the commutator motor at least one further contact element 25 assigned to the component 31 is arranged in the female connector 28.
Patent NZ-568822-A (NZ)
Title: Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
Inventor: POLLENTIER STEPHANE
IPC: A61K31/496
Filed: 2006-11-06
Abstract: Disclosed is the use of flibanserin, the pharmacologically acceptable acid addition salts for the preparation of a medicament for the treatment of pre-menopausal Sexual Desire Disorders in women.
Patent NZ-571196-A (NZ)
Title: Dihydropyrazolopyrimidinone derivatives
Inventor: NISHIBATA TOSHIHIDE
IPC: A61K31/519
Filed: 2007-04-25
Abstract: Disclosed are dihydropyrazolopyrimidinone derivatives of formula (I) wherein A1 is a pyrimidine or piperazine moiety of formula (aa1) and the rest of the substituents are disclosed within the specification. Also disclosed is the use of the said compounds for the manufacture of a medicament for the treatment of cancer.
Patent NZ-571209-A (NZ)
Title: Lighting device and lighting system for stimulating plant growth
Inventor: ROOYMANS JOHANNES OTTO
IPC: A01G7/04
Filed: 2007-02-13
Abstract: A lighting device for stimulating plant growth comprises at least one solid state light source, suitable for emitting light of at least one wavelength within a predetermined wavelength range. The at least one solid state light source is adapted for connection to an electrical network, and the at least one solid state light source is in contact with a cooling medium, and the lighting device is further provided with a first tube, at least part of it being transparent for light from a predetermined wavelength range. The at least one solid state light source is positioned in the first tube. The cooling medium has a temperature in a temperature range between -50 and 00C. The lighting device is further provided with a third tube with a smaller diameter than the first tube and is positioned such that it is enclosed by the first tube. The third tube is a metal tube suitable for receiving the cooling medium and is provided with a supply opening and a discharge opening for respectively supplying and discharging the cooling medium and wherein the at least one solid state light source is positioned in contact with the third tube between the first and the third tube.
Patent NZ-573288-A (NZ)
Title: A locking device for racking system
Inventor: BERRY PAUL ARMSTRONG
IPC: A47B57/16
Filed: 2007-05-23
Abstract: Disclosed is a locking device for an adjustable racking system. The system is adapted to resist upward movement of a first component relative to a second component. The components each have a number of holes including first and second sets of aligned holes. The first and second components are interconnected by a first locking formation which extends through the first set of aligned holes, and a second locking formation which extends through the second set of aligned holes.
Patent NZ-574586-A (NZ)
Title: Irrigation system which applies a predetermined amount of NPK based on application depth and flow rate
Inventor: BOSCH MATTHEW VAN DEN
IPC: A01C23/00
Filed: 2009-01-30
Abstract: Disclosed is an automated sprinkler irrigation apparatus (1). The apparatus includes: inlet means (13) connected to an irrigation effluent water source; a manifold (5) connected to the inlet; at least two control valves (3) connected to the manifold; sprinkler means connected to the valves to distribute the irrigation in a predetermined manner; a flow meter (8); and a controller (6). The flow meter provides feedback to the controller of the flow through the valves, and the controller actuates the valves in a sequential cycle so the sprinkler is given a predetermined amount of irrigation. The sprinkler can then deliver a predetermined amount of NPK dependent on effluent application depth and the flow rate, such that dispersion of the water allows absorption of nutrients into a ground surface while reducing run-off.
Patent NZ-577455-A (NZ)
Title: Label-free methods for cell binding assays using a colorimetric resonant reflectance optical biosensor
Inventor: LIN BO
IPC: C12Q1/68
Filed: 2004-09-22
Abstract: A method of detecting cells comprising applying one or more types of cells to a surface comprising a colormetric resonant reflectance optical biosensor. The cells are bound to the surface by a specific binding substance selected from nucleic acids, proteins, antibody, antigen, small organic molecules, other cells, virus, bacteria, polymer and biological sample. Binding is then directly detected without washing the biosensor surface by illuminating the vessel with light. A shift in the peak wavelength values is indicative of specific binding substance-to-cell binding. The method can also be applied to detect binding of molecules involved in cell adhesion, cell migration, cell chemotaxis and cell invasion. (62) Divided Out of 546636
Patent NZ-578756-A (NZ)
Title: Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr
Inventor: BANCHEREAU JACQUES F
IPC: A61K35/12
Filed: 2008-02-02
Abstract: Disclosed is an ex vivo method for increasing the effectiveness of antigen presentation by an isolated antigen presenting cell comprising the steps of providing an isolated DC-ASGPR-specific antibody or functional fragment thereof to which an antigen is attached, wherein the isolated DC-ASGPR-specific antibody or functional fragment thereof is bound to one half of a Coherin/Dockerin pair and an antigen is bound to the complementary half of the Coherin/Dockerin pair to form a complex; and contacting the isolated antigen presenting cell with the complex, wherein the antigen is processed and presented by the antigen-presenting cell that has been contacted with the complex. Also disclosed is the use of antibodies or other specific binding molecules capable of specifically binding to the extracellular domain of DC-ASGPR, wherein the antibodies or other specific binding molecules are bound to one half of a Coherin/Dockerin pair and one or more antigens are bound to a complementary half of the Coherin/Dockerin pair in the manufacture of a medicament for delivering antigens to antigen-presenting cells for the purpose of eliciting protective or therapeutic immune responses against cancer or an infectious disease selected from the group consisting of bacterial, viral, fungal, or protozoal disease.
Patent NZ-580896-A (NZ)
Title: Microemulsions and their use for improving the biological efficacy of pesticides
Inventor: BOHUS PETER
IPC: C09K23/00
Filed: 2007-10-25
Abstract: Disclosed is a microemulsion containing a) a mixture of surfactants comprising: i) one or more anionic derivatives of an alkylpolyglycoside; ii) one or more alkylpolyglycosides; iii) one or more anionic derivatives of a fatty alcohol; b) one or more vegetable oils, or one or more methyl esters of fatty acids deriving from the transesterification of vegetable oils, or a mixture thereof; c) one or more non-ionic surfactants; d) water.
Patent NZ-591096-A (NZ)
Title: Flexible forehead support with flexible portion with cut-outs or recesses to control flexing of forehead support relative to mask frame
Inventor: FLOWER NEE DOHERTY RENEE FRANCES
IPC: A61M16/06
Filed: 2008-06-19
Abstract: À respiratory mask includes à mask frame and à forehead support provided to the mask frame. The forehead support includes à base extending from the frame. The base includes à flexible portion along at least à portion of its length including à material and/or physical characteristic that allows the base to flex from an original, unloaded position. The flexible portion has one or more recesses or cut-outs structured to control the amount and location of flexing.
Patent NZ-594664-A (NZ)
Title: Meter that selectively connects single-phase outputs to multi-phase inputs in response to a received control signal
Inventor: HENDERIECKX LUC
IPC: H02J13/00
Filed: 2010-02-08
Abstract: Disclosed is a smart metering device (10) for connecting an end user mains network to a multiple-phase power distribution network and monitoring consumption on the end user mains network. The device comprises inputs (L1, L2, L3) for connecting the smart metering device to multiple phases of the multiple phase power distribution network and single-phase low- voltage outputs (1, 2) for connecting the end user mains network to the smart metering device. The device also includes a power circuit (5) between the inputs and the low-voltage outputs. The power circuit (5) comprises a phase selector (4) comprising input switches for switching the low voltage outputs (1, 2) between different sets of the inputs (L1, L2, L3), each set corresponding to one of the multiple phases of the multiple-phase power distribution network. A modem (6) is included for receiving control messages sent from a communication server associated with the power distribution network. A controller (3) is communicatively coupled to the modem (6) and the phase selector (4) for controlling switching operations in the smart metering device in response to the control messages. Each single-phase low-voltage output has an output switch (21, 22) communicatively coupled with the controller (3) for switching off a part of the end user mains network which is connected to the respective single phase low voltage output (1, 2). The controller is adapted to operate the output switches (21, 22) to switch off said parts of the end user mains network before operating the phase selector (4).
Patent NZ-596610-A (NZ)
Title: A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
Inventor: KIM KYUNG-HEE
IPC: A61K47/34
Filed: 2010-05-27
Abstract: 596610 Provided are microspheres with improved bioavailability containing poorly water-soluble drugs, oral preparations comprising same, and a method for preparing same. The microspheres containing poorly water-soluble drugs are solid dispersions in which poorly water-soluble drugs are dispersed into non-crystalline forms in a water-soluble macromolecular carrier, the microsphere is prepared by spray drying a mixed solution containing the water-soluble polymer carrier and the poorly soluble drug dissolved in a mixed solvent of water and an organic solvent and have the advantages of improving the bioavailability of poorly water-soluble drugs. Wherein the microsphere does not comprise a surfactant, the weight ratio of the organic solvent and water is 0.5:1 to 5:1, the water-soluble polymer carrier is hydroxypropylmethylcellulose (HPMC), and the poorly soluble drug is selected from the group consisting of acyclovir, candesartan, eprosartan, fenofibrate, lovastatin, megestrol, simvastatin, sirolimus, tacrolimus and a combination thereof, and the spray drying is conducted at a spray temperature of 80°C to 120°C, a spray speed of 3,000 rpm to 5,000 rpm, and an injection speed of 10ml/min to 100ml/min, using an atomizer type spray dryer.
Patent NZ-600342-A (NZ)
Title: Carboxamide compounds and their use as calpain inhibitors
Inventor: MOLLER ACHIM
IPC: A61K31/4015
Filed: 2010-12-21
Abstract: 600342 Provided are carboxamide compounds of the general formula (I), where R1, R2, R3 R4, R5, m and n are as described in the specification. Preferred compounds are those where R1 is an optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is an optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C1-C3-alkyl, C1-C3-haloalkyl, C2-C4- alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, or phenyl-C1-C3-alkyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1. The compounds are inhibitors of calpain (calcium dependant cysteine proteases). Further provided is the use of the compounds for treating disorders associated with elevated calpain activity such as ischemias of the heart, the kidney, the lung, the liver or the central nervous system, muscular dystrophies, cataracts of the eyes, diabetes, HIV disorders, neurodegenerative diseases, multiple sclerosis and infectious diseases.
Patent NZ-603594-A (NZ)
Title: Certain amino-pyrimidines, compositions thereof, and methods for their use
Inventor: COLLIBEE SCOTT
IPC: C07D413/14
Filed: 2011-04-22
Abstract: 603594 Disclosed are 5-aryl-2-alkylamino-pyrimidine derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from hydrogen, halogen, CN, alkyl, haloalkyl, ORa, and NRbRc; R2 is selected from 3-8 membered heterocycloalkenyl, C6-10 aryl, and 5-10 membered heteroaryl wherein each of the 3-8 membered heterocycloalkenyl, C6-10 aryl and 5-10 membered heteroaryl groups is optionally substituted; R3 is selected from hydrogen, halogen, CN, alkyl, haloalkyl, ORa, and NRbRc; R4 is selected from hydrogen and alkyl; R5 and R6 are each independently selected from alkyl, or alternatively, R5 and R6 together with the carbon atom to which they are bound form C3-8 cycloalkyl which is optionally substituted; R7 is selected from C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted; R8 and R9, at each occurrence, are each independently selected from hydrogen, halogen and alkyl; X is a bond; m is 0, 1 or 2; and wherein the remaining substituents are as defined herein. Representative compounds include 4-fluoro-3-(2-{ [2-(3-fluoro(2-pyridyl))-2-methylpropyl]amino} pyrimidin-5-yl)benzamide, 4-fluoro-3-[2-({ [(3-fluoro-(2-pyridyl))cyclobutyl]methyl} amino)pyrimidin-5-ylibenzamide, 4-fluoro-3-[2-({ [3-fluoro-1-(3-fluoro-(2-pyridyl))cyclobutyl]methyl} amino)pyrimidin-5-yl]benzamide, { 4-fluoro-3-[2-({ [trans-3-fluoro-1-(3-fluoro-(2-pyridyl))cyclobutyl]methyl} amino)pyrimidin-5-yl]phenyl} -N-methylcarboxamide, 4-fluoro-3-(2-((trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2-hydroxybenzamide, 3-(2-((trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxy-N-methyl-benzamide, 4-[2-({ [(3-fluoro-2-pyridyl)cyclobutyl]methyl} amino)pyrimidin-5-yl]pyridine-2-carboxamide, 4-[2-({ [3-fluoro-1-(3-fluoro-(2-pyridyl))cyclobutyl]methyl} amino)pyrimidin-5-yl]pyridine-2-carboxamide, 1-[2-({ [trans-3-fluoro-1-(3-fluoro-(2-pyridyl))cyclobutyl]methyl} amino)pyrimidin-5-yl]pyrazole-4-carboxamide, 1-(2-(((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide, 2-(2-(2-((1-(3-chloropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazol-5-yl)acetamide, 2-(2-((3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazole-5-carboxamide and 2-(2-((trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazole-5-carboxamide. Further disclosed is a pharmaceutical composition comprising a compound as defined above, or a pharmaceutically acceptable salt thereof, for the treatment of a disease or condition selected from neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation-related deficits, peripheral vascular disease, peripheral arterial disease, frailty, muscle atrophy and fatigue, metabolic syndrome, chronic fatigue syndrome, and obesity.